Regulatory

Share or bookmark this intelligence view.

Regulatory precedents and guidance mapped to active intelligence signals.

FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to AZURITY; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generics of Gilotrif (afatinib) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Barr; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Barr; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Barr; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (cardiology) as Hetero Labs Ltd; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Mylan; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Mylan; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Mylan; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to SHORLA; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to SHORLA; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Gilead; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Gilead; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Galderma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Galderma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generics of Gilotrif (afatinib) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Galderma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (colorectal cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (colorectal cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (colorectal cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as AstraZeneca; the shared ADC mechanism makes the regulatory bar more directly transferable.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (prostate cancer) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (prostate cancer) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Roche; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Veklury; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Veklury; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generics of Gilotrif (afatinib) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Veklury; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Veklury; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Veklury; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
safety guidance95% confidence
FDA AP — PADCEV (SUPPL)
Why relevant: Why this matters: sets a safety guidance precedent in the same sub-indication (bladder cancer) as Pfizer; the shared ADC mechanism makes the regulatory bar more directly transferable; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Pfizer; the shared ADC mechanism makes the regulatory bar more directly transferable; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (rare disease) as Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (rare disease) as Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (rare disease) as Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (rare disease) as Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to TYENNE; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to TYENNE; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Lacosamide; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Lacosamide; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clonazepam; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clonazepam; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Granules; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Granules; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (ild) as Bayer; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
CDER proposes to withdraw approval of TAVNEOS
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to TYENNE; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to TYENNE; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to AbbVie; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to AbbVie; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Incyte; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Incyte; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clomiphene Citrate brands; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
CDER proposes to withdraw approval of TAVNEOS
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Clomiphene Citrate brands; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves First Generic of Priftin (rifapentine) Tablets
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (ild) as Lipfendra; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (ild) as Lipfendra; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (ild) as Lipfendra; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Natural Disaster Preparedness and Response | Drugs
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Ferring; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (cardiology) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (ild) as Merck; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (ild) as Merck; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
CDER proposes to withdraw approval of TAVNEOS
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Novartis; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to REVTORPYK; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hospira; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hospira; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Understanding the Risks of Compounded Drugs
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to IMPAX; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Astellas; the shared ADC mechanism makes the regulatory bar more directly transferable; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (her2) as palbociclib; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (her2) as palbociclib; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (her2) as palbociclib; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Argatroban; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as Eli Lilly; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as Eli Lilly; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: sets a approval precedent in the same sub-indication (cardiology) as BELOTECA; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
safety guidance95% confidence
FDA AP — CANAGLIFLOZIN (ORIG)
Why relevant: Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to APOTEX; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
safety guidance95% confidence
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Why relevant: Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to APOTEX; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
safety guidance95% confidence
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Why relevant: Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to APOTEX; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
safety guidance95% confidence
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Why relevant: Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to APOTEX; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
safety guidance95% confidence
FDA TA — ANDA218552
Why relevant: Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to APOTEX; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
Withdrawn | Cancer Accelerated Approvals
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Sodium Bicarbonate; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source
FDA
approval95% confidence
CDER proposes to withdraw approval of TAVNEOS
Why relevant: Why this matters: illustrates how regulators handled a comparable approval decision relevant to Sodium Bicarbonate; the same agency is already in play for this signal, so precedent weight is higher.
FDA document
View source